{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:14:59Z","timestamp":1785838499895,"version":"3.56.0"},"reference-count":95,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2020,10,31]]},"DOI":"10.5582\/bst.2020.03240","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T22:05:54Z","timestamp":1598220354000},"page":"328-341","source":"Crossref","is-referenced-by-count":52,"title":["Systemic treatment of advanced or recurrent biliary tract cancer"],"prefix":"10.5582","volume":"14","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangtai","family":"Cao","sequence":"additional","affiliation":[{"name":"Cangzhou Hospital of Integrated TCM-WM Cangzhou, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin's Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma \u2013 Evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018; 15:95-111.","DOI":"10.1038\/nrclinonc.2017.157"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 2016; 21:594-599.","DOI":"10.1634\/theoncologist.2015-0446"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Raoof M, Singh G. Rising trends in intrahepatic cholangiocarcinoma incidence and mortality: getting at the root cause. Hepatobil Surg Nutr. 2019; 8:301-303.","DOI":"10.21037\/hbsn.2019.01.15"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001; 48:816-820.","DOI":"10.1136\/gut.48.6.816"},{"key":"5","unstructured":"5. Yamamoto S. Biliary tract cancer mortality rates by prefectures in Japan. Jpn J Clin Oncol. 2000; 30:576."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, Bray F, McGlynn KA, Petrick JL. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020; 126:2666-2678.","DOI":"10.1002\/cncr.32803"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245:755-762.","DOI":"10.1097\/01.sla.0000251366.62632.d3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cai Y, Cheng N, Ye H, Li F, Song P, Tang W. The current management of cholangiocarcinoma: A comparison of current guidelines. Biosci Trends. 2016; 10:92-102.","DOI":"10.5582\/bst.2016.01048"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jeong S, Cheng Q, Huang L, Wang J, Sha M, Tong Y, Xia L, Han L, Xi Z, Zhang J, Kong X, Gu J, Xia Q. Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection. BMC Cancer. 2017; 17:464.","DOI":"10.1186\/s12885-017-3464-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, Yamaguchi R, Nagino M. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017; 104:426-433.","DOI":"10.1002\/bjs.10452"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: Analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018; 163:732-738.","DOI":"10.1016\/j.surg.2017.08.011"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362:1273-1281.","DOI":"10.1056\/NEJMoa0908721"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study. Br J Cancer. 2008; 99:862-867.","DOI":"10.1038\/sj.bjc.6604628"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Morizane C, Okusaka T, Mizusawa J, <i>et al.<\/i> Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019; 30:1950-1958.","DOI":"10.1093\/annonc\/mdz402"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB, 3rd, O&apos;Dwyer PJ. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2018; 4:1707-1712.","DOI":"10.1001\/jamaoncol.2018.3277"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Roth MT, Goff LW. Gemcitabine, cisplatin, and nab-paclitaxel for patients with advanced biliary tract cancer: Closing the GAP. JAMA Oncol. 2019; 5:831-832.","DOI":"10.1001\/jamaoncol.2019.0269"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. JAMA Oncol. 2019; 5:824-830.","DOI":"10.1001\/jamaoncol.2019.0270"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Belkouz A, de Vos-Geelen J, Mathot RAA, Eskens F, van Gulik TM, van Oijen MGH, Punt CJA, Wilmink JW, Klumpen HJ. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: An open-label, single arm, phase 2 trial. Br J Cancer. 2020; 122:634-639.","DOI":"10.1038\/s41416-019-0698-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, Neuzillet C, Malka D, Manfredi S, Desrame J. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II\/III study. Dig Liver Dis. 2019; 51:318-320.","DOI":"10.1016\/j.dld.2018.11.018"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017; 123:1979-1988.","DOI":"10.1002\/cncr.30571"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK, Lim HY. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study. Eur J Cancer. 2012; 48:196-201.","DOI":"10.1016\/j.ejca.2011.11.017"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Moehler M, Maderer A, Schimanski C, <i>et al.<\/i> Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer. 2014; 50:3125-3135.","DOI":"10.1016\/j.ejca.2014.09.013"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015; 21:2096-2101.","DOI":"10.3748\/wjg.v21.i7.2096"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ferraro D, Goldstein D, O&apos;Connell RL, <i>et al.<\/i> TACTIC: A multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer Chemother Pharmacol. 2016; 78:361-367.","DOI":"10.1007\/s00280-016-3089-4"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Vogel A, Kasper S, Bitzer M, <i>et al.<\/i> PICCA study: Panitumumab in combination with cisplatin\/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-A randomised biomarker-driven clinical phase II AIO study. Eur J Cancer. 2018; 92:11-19.","DOI":"10.1016\/j.ejca.2017.12.028"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Leone F, Marino D, Cereda S, <i>et al.<\/i> Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer. 2016; 122:574-581.","DOI":"10.1002\/cncr.29778"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Malka D, Cervera P, Foulon S, <i>et al.<\/i> Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014; 15:819-828.","DOI":"10.1016\/S1470-2045(14)70212-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lee J, Park SH, Chang HM, <i>et al.<\/i> Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012; 13: 181-188.","DOI":"10.1016\/S1470-2045(11)70301-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Medical treatment for cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:123-142.","DOI":"10.1111\/liv.14100"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Wardell CP, Fujita M, Yamada T, <i>et al.<\/i> Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018; 68:959-969.","DOI":"10.1016\/j.jhep.2018.01.009"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nakamura H, Arai Y, Totoki Y, <i>et al.<\/i> Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47:1003-1010.","DOI":"10.1038\/ng.3375"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Lowery MA, Bradley M, Chou JF, <i>et al.<\/i> Binimetinib plus gemcitabine and cisplatin phase I\/II trial in patients with advanced biliary cancers. Clin Cancer Res. 2019; 25:937-945.","DOI":"10.1158\/1078-0432.CCR-18-1927"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Xue L, Guo C, Zhang K, Jiang H, Pang F, Dou Y, Liu X, Lin H, Dong X, Zhao S, Yao M, Wang K, Feng Y, Gu W. Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. Hepatobiliary Surg Nutr. 2019; 8:615-622.","DOI":"10.21037\/hbsn.2019.08.05"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Montal R, Sia D, Montironi C, <i>et al.<\/i> Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020; 73:315-327.","DOI":"10.1016\/j.jhep.2020.03.008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yang P, Javle M, Pang F, <i>et al.<\/i> Somatic genetic aberrations in gallbladder cancer: Comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2019; 8:604-614.","DOI":"10.21037\/hbsn.2019.04.11"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Lowery MA, Ptashkin R, Jordan E, <i>et al.<\/i> Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin Cancer Res. 2018; 24:4154-4161.","DOI":"10.1158\/1078-0432.CCR-18-0078"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Goyal L, Saha SK, Liu LY, <i>et al.<\/i> Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017; 7:252-263.","DOI":"10.1158\/2159-8290.CD-16-1000"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Javle M, Lowery M, Shroff RT, <i>et al.<\/i> Phase II Study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018; 36 276-282.","DOI":"10.1200\/JCO.2017.75.5009"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Javle M, Borbath I, Clarke S, <i>et al.<\/i> Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: The PROOF trial. Ann Oncol. 2019; 30 Suppl 4: iv62.","DOI":"10.1093\/annonc\/mdz155.224"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, <i>et al.<\/i> Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019; 120:165-171.","DOI":"10.1038\/s41416-018-0334-0"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Abou-Alfa GK, Sahai V, Hollebecque A, <i>et al.<\/i> Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21:671-684.","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Krook MA, Lenyo A, Wilberding M, <i>et al.<\/i> Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020; 19:847-857.","DOI":"10.1158\/1535-7163.MCT-19-0631"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Yang T, Liang L, Wang MD, Shen F. FGFR inhibitors for advanced cholangiocarcinoma. Lancet Oncol. 2020; 21:610-612.","DOI":"10.1016\/S1470-2045(20)30152-2"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Goyal L, Shi L, Liu LY, <i>et al.<\/i> TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discovery. 2019; 9:1064-1079.","DOI":"10.1158\/2159-8290.CD-19-0182"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Goyal L, Govindan A, Sheth RA, <i>et al.<\/i> Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist. 2015; 20:1019-1027.","DOI":"10.1634\/theoncologist.2015-0210"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Jiao Y, Pawlik TM, Anders RA, <i>et al.<\/i> Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45:1470-1473.","DOI":"10.1038\/ng.2813"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Wang P, Dong Q, Zhang C, <i>et al.<\/i> Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013; 32:3091-3100.","DOI":"10.1038\/onc.2012.315"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Kucukyurt S, Eskazan AE. New drugs approved for acute myeloid leukaemia in 2018. Br J Clin Pharmacol. 2019; 85:2689-2693.","DOI":"10.1111\/bcp.14105"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Lowery MA, Burris HA 3rd, Janku F, <i>et al.<\/i> Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study. Lancet Gastroenterol Hepatol. 2019; 4:711-720.","DOI":"10.1016\/S2468-1253(19)30189-X"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Abou-Alfa GK, Macarulla T, Javle MM, <i>et al.<\/i> Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21:796-807.","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Furuse J, Nagashima F. Inhibitor of MEK1\/2, selumetinib, for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2011; 5:579-581.","DOI":"10.1586\/egh.11.58"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW. A phase 1b study of selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: The ABC-04 study. BMC Cancer. 2016; 16:153.","DOI":"10.1186\/s12885-016-2174-8"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer. 2020; 130:219-227.","DOI":"10.1016\/j.ejca.2020.01.026"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Shroff RT, Yarchoan M, O&apos;Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017; 116:1402-1407.","DOI":"10.1038\/bjc.2017.119"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Finn RS, Ahn DH, Javle MM, Tan BR, Jr., Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018; 36:1037-1043.","DOI":"10.1007\/s10637-018-0600-2"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kim JW, Lee KH, Suh KJ, Nam AR, Bang JH, Bang YJ, Oh DY. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS\/RAF\/MEK\/ERK pathway: Phase Ib study. Br J Cancer. 2019; 121:332-339.","DOI":"10.1038\/s41416-019-0523-5"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, Giannone V, D&apos;Amelio AM, Jr., Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF (V600E)-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 2017; 18:1307-1316.","DOI":"10.1016\/S1470-2045(17)30679-4"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Robert C, Grob JJ, Stroyakovskiy D, <i>et al.<\/i> Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019; 381:626-636.","DOI":"10.1056\/NEJMoa1904059"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Bunyatov T, Zhao A, Kovalenko J, Gurmikov B, Vishnevsky V. Personalised approach in combined treatment of cholangiocarcinoma: A case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol. 2019; 10:815-820.","DOI":"10.21037\/jgo.2019.03.05"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Lavingia V, Fakih M. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol. 2016; 7:E98-E102.","DOI":"10.21037\/jgo.2016.09.13"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Loaiza-Bonilla A, Clayton E, Furth E, O&apos;Hara M, Morrissette J. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: Implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience. 2014; 8:479.","DOI":"10.3332\/ecancer.2014.479"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Kocsis J, Arokszallasi A, Andras C, Balogh I, Beres E, Deri J, Petak I, Janvary L, Horvath Z. Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: Dramatic clinical and radiological response with a confusing synchronic new liver lesion. J Gastrointest Oncol. 2017; 8:E32-E38.","DOI":"10.21037\/jgo.2017.01.06"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Oh DY, Bang YJ. HER2-targeted therapies \u2013 A role beyond breast cancer. Nat Rev Clin Oncol. 2020; 17:33-48.","DOI":"10.1038\/s41571-019-0268-3"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine\/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase I trial with an extensive biomarker program. BMC Cancer. 2019; 19:55.","DOI":"10.1186\/s12885-018-5223-7"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009; 64:777-783.","DOI":"10.1007\/s00280-009-0927-7"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jager D, Frohling S, Springfeld C. Durable remission under dual HER2 blockade with trastuzumab and pertuzumab in a patient with metastatic gallbladder cancer. Z Gastroenterol. 2016; 54:426-430. (in German).","DOI":"10.1055\/s-0042-103498"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Ye M, Lv J, Xu G, Wang W, Jing Y, Sun A, Lu Z, Wu X, Liu Y, Shao YW, Liu F, Tao F. Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. J Int Med Res. 2019; 47:2768-2777.","DOI":"10.1177\/0300060519847796"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2\/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015; 8:58.","DOI":"10.1186\/s13045-015-0155-z"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018; 36:536-542.","DOI":"10.1200\/JCO.2017.75.3780"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Hyman DM, Piha-Paul SA, Won H, <i>et al.<\/i> HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018; 554:189-194.","DOI":"10.1038\/nature25475"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: A multicenter retrospective study. Oncologist. 2017; 22:804-810.","DOI":"10.1634\/theoncologist.2016-0415"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Zhang W, Shi J, Li R, Han Z, Li L, Li G, Yang B, Yin Q, Wang Y, Ke Y, Li Q. Effectiveness of olaparib treatment in a patient with gallbladder cancer with an ATM-inactivating mutation. Oncologist. 2020; 25:375-379.","DOI":"10.1634\/theoncologist.2019-0498"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Ascierto PA, Long GV, Robert C, <i>et al.<\/i> Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019; 5:187-194.","DOI":"10.1001\/jamaoncol.2018.4514"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Robert C, Long GV, Brady B, <i>et al.<\/i> Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372:320-330.","DOI":"10.1056\/NEJMoa1412082"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Borghaei H, Paz-Ares L, Horn L, <i>et al.<\/i> Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373:1627-1639.","DOI":"10.1056\/NEJMoa1507643"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Sharma P, Retz M, Siefker-Radtke A, <i>et al.<\/i> Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18:312-322.","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Motzer RJ, Escudier B, McDermott DF, <i>et al.<\/i> Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803-1813.","DOI":"10.1056\/NEJMoa1510665"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Ferris RL, Blumenschein G Jr., Fayette J, <i>et al.<\/i> Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016; 375:1856-1867.","DOI":"10.1056\/NEJMoa1602252"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. El-Khoueiry AB, Sangro B, Yau T, <i>et al.<\/i> Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017; 389:2492-2502.","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020; 72:353-363.","DOI":"10.1016\/j.jhep.2019.10.009"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Gou M, Zhang Y, Si H, Dai G. Efficacy and safety of nivolumab for metastatic biliary tract cancer. Onco Targets Ther. 2019; 12:861-867.","DOI":"10.2147\/OTT.S195537"},{"key":"82","doi-asserted-by":"publisher","unstructured":"82. Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer. JAMA oncology. 2020; doi: 10.1001\/jamaoncol.2020.0930.","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Ioka T, Ueno M, Oh DY, Fujiwara Y, Chen JS, Doki Y, Mizuno N, Park K, Asagi A, Hayama M, Nii M, Komuro K, Sugimoto M, Vlahovic G, Keda M. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). Gastrointestinal Cancers Symposium; 2019; San Francisco, CA. J Clin Oncol. 2019; 37:suppl 387-387.","DOI":"10.1200\/JCO.2019.37.4_suppl.387"},{"key":"84","doi-asserted-by":"publisher","unstructured":"84. Piha-Paul SA, Oh DY, Ueno M, <i>et al.<\/i> Efficacy and safety of Pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020; May 2. doi: 10.1002\/ijc.33013.","DOI":"10.1002\/ijc.33013"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Kang J, Jeong JH, Hwang HS, <i>et al.<\/i> Efficacy and safety of Pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response. Cancer research and treatment. 2020; 52:594-603.","DOI":"10.4143\/crt.2019.493"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: Nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018; 23:1407-e1136.","DOI":"10.1634\/theoncologist.2018-0044"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: A non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019; 4:611-621.","DOI":"10.1016\/S2468-1253(19)30086-X"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Lu JC, Zeng HY, Sun QM, <i>et al.<\/i> Distinct PD-L1\/PD1 Profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors. Theranostics. 2019; 9:4678-4687.","DOI":"10.7150\/thno.36276"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Kitano Y, Yamashita YI, Nakao Y, <i>et al.<\/i> Clinical significance of PD-L1 expression in both cancer and stroma cells of cholangiocarcinoma patients. Ann Surg Oncol. 2020; 27:599-607.","DOI":"10.1245\/s10434-019-07701-4"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Yu F, Gong L, Mo Z, Wang W, Wu M, Yang J, Zhang Q, Li L, Yao J, Dong J. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. Biosci Trends. 2019; 13:58-69.","DOI":"10.5582\/bst.2019.01003"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Chen WX, Li GX, Hu ZN, Zhu P, Zhang BX, Ding ZY. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. Medicine (Baltimore). 2019; 98:e17832.","DOI":"10.1097\/MD.0000000000017832"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer. 2019; 7:204.","DOI":"10.1186\/s40425-019-0692-z"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Alshari OM, Dawaymeh TA, Tashtush NA, Aleshawi AJ, Al Manasra ARA, Obeidat KA. Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: A report of two cases. Onco Targets Ther. 2019; 12:5293-5298.","DOI":"10.2147\/OTT.S197559"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Sui M, Li Y, Wang H, Luo Y, Wan T, Wang X, Hu B, Cheng Y, Lv X, Xin X, Xu Q, Wang G, Lu S. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer. 2019; 7:125.","DOI":"10.1186\/s40425-019-0596-y"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Mou H, Yu L, Liao Q, Hou X, Wu Y, Cui Q, Yan N, Ma R, Wang L, Yao M, Wang K. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: A case report. BMC Cancer. 2018; 18:1105.","DOI":"10.1186\/s12885-018-5021-2"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/5\/14_2020.03240\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:44:37Z","timestamp":1604720677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/5\/14_2020.03240\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2020.03240","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]}}}